Non-Cutaneous Melanoma

histology

Identifier: CI-CAN-00001283
Entity page: /cancer/non-cutaneous-melanoma ↗
Edges: 486

Neighbours: 15 genes15 drugs10 trials
Drawn: 40 of 40 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Non-Cutaneous Melanoma approved for …APPROVED_FORderived2 of 2
← approved for	Tebentafuspother EMA (EU) · approved · 2022-04-01 · Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable o…	—	approved	Uveal Melanoma	1	Regulatory	ema	graph →
← approved for	Tebentafusp

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

GNAQ Mutation Cabozantinib1 active / 2 trials
Curatedlevel Bsensitivity· support 1civicObservedGNAQ altered in 50% (40 / 80 cases, largest of 3 cohorts)no approval record in this cancercontext: Uveal Melanoma
GNAQ Mutation TrametinibFDA US 2013-05-29 · tumour-agnostic1 active / 3 trials
Curatedlevel Bsensitivity· support 1civicObservedGNAQ altered in 50% (40 / 80 cases, largest of 3 cohorts)Regulatoryapproved (2 approval records)context: Uveal Melanoma
GNA11 Mutation Cabozantinib1 active / 2 trials
Curatedlevel Bsensitivity· support 1civicObservedGNA11 altered in 45% (36 / 80 cases, largest of 3 cohorts)no approval record in this cancercontext: Uveal Melanoma
GNAQ Q209 Refametinib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedGNAQ altered in 50% (40 / 80 cases, largest of 3 cohorts)no approval record in this cancercontext: Uveal Melanoma
GNA11 Mutation TrametinibFDA US 2013-05-29 · tumour-agnostic1 active / 3 trials
Curatedlevel Csensitivity· support 1civicObservedGNA11 altered in 45% (36 / 80 cases, largest of 3 cohorts)Regulatoryapproved (2 approval records)context: Uveal Melanoma
KIT Internal Duplication Imatinib0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for KIT in this cancerno approval record in this cancercontext: Anal Melanoma
KIT K642E Imatinib0 active / 1 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for KIT in this cancerno approval record in this cancercontext: Mucosal Melanoma
NRAS Q61L Belvarafenib0 active / 0 trials
Curatedlevel Csensitivity· support 1civicObservedcohort frequency not yet available for NRAS in this cancerno approval record in this cancercontext: Mucosal Melanoma

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Non-Cutaneous Melanoma altered in cohorts of …ALTERED_INderived15 of 100show all (up to 200)
← altered in cohorts of	CCN4 62 / 80 cases (78 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	SLC45A4 61 / 80 cases (76 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	AARD 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ADCY8 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	AGO2 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ANXA13 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ASAP1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	ATAD2 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	C8orf76 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	CCN3 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	CHRAC1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	COL14A1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	COL22A1 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	COLEC10 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →
← altered in cohorts of	CYRIB 60 / 80 cases (75 %) · ssm · TCGA-UVM	—	—	Uveal Melanoma	1	Observed	gdc	graph →

Non-Cutaneous Melanoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 72show all (up to 200)
→ investigated in trials for	Ipilimumabmonoclonal antibody 35 trials (9 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	35	Observed	clinicaltrials	graph →
→ investigated in trials for	Nivolumabmonoclonal antibody 30 trials (12 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 21 trials (9 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Aldesleukinother 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Tebentafuspother 10 trials (7 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Dacarbazinesmall molecule 7 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 6 trials (2 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Melphalansmall molecule 6 trials (3 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Temozolomidesmall molecule 6 trials (0 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 5 trials (2 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Sunitinibsmall molecule 5 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Afliberceptother 4 trials (1 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Binimetinibsmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Crizotinibsmall molecule 4 trials (3 active) · roll-up of the cancer and its descendants	—	—	Non-Cutaneous Melanoma	4	Observed	clinicaltrials	graph →

Non-Cutaneous Melanoma studied in …STUDIED_INderived10 of 312show all (up to 200)
→ studied in	NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 312 trials mapped (101 active)	—	—	Mucosal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04462406Phase 2 · active not recruiting Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial · condition mapped CURATED_BROADER · 312 trials mapped (101 active)	—	—	Mucosal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04511013Phase 2 · recruiting A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases · condition mapped CURATED_BROADER · 312 trials mapped (101 active)	—	—	Mucosal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05524935Phase 2 · active not recruiting Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 312 trials mapped (101 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05607095Phase 1 · recruiting A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma · condition mapped ONTOLOGY_EXACT · 312 trials mapped (101 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804186Phase 3 · recruiting Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma · condition mapped ONTOLOGY_EXACT · 312 trials mapped (101 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00937937Phase 2 · active not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma · condition mapped ONTOLOGY_EXACT · 312 trials mapped (101 active)	—	—	Mucosal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02678572Phase 3 · completed Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma · condition mapped ONTOLOGY_EXACT · 312 trials mapped (101 active)	—	—	Ocular Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05546827Phase 2 · recruiting Preoperative Radiotherapy and Immunotherapy for Sinonasal and Anorectal Mucosal Melanoma · condition mapped ALIAS · 312 trials mapped (101 active)	—	—	Sinonasal Mucosal Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05903937Phase 1 · not yet recruiting Locoregional Administration of TIL and Lymphodepletion in Patients With Melanoma and Liver Metastases · condition mapped ONTOLOGY_EXACT · 312 trials mapped (101 active)	—	—	Uveal Melanoma	1	Observed	clinicaltrials	graph →